Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Expanded therapeutic range of valproate.

D L Hurst1

  • 1Child Neurology Clinic, Fitzsimons Army Medical Center, Aurora, Colorado.

Pediatric Neurology
|November 1, 1987
PubMed
Summary

Higher valproate levels (100-200 mcg/ml) in pediatric epilepsy patients improved seizure control. Nondose-related side effects were not observed, suggesting increased valproate dosage may enhance treatment response.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nonreciprocal Transmission and Reflection of a Chirally Coupled Quantum Dot.

Nano letters·2018
Same author

Methsuximide therapy of juvenile myoclonic epilepsy.

Seizure·1996
Same author

The use of felbamate to treat infantile spasms.

Journal of child neurology·1995
Same author

Tolstoy's description of Tourette syndrome in Anna Karenina.

Journal of child neurology·1994
Same author

The rapid change to monotherapy with valproic acid in children.

Journal of child neurology·1993
Same author

Early severe infantile botulism.

The Journal of pediatrics·1993

Area of Science:

  • Pediatric Neurology
  • Clinical Pharmacology

Background:

  • Valproate is a common antiepileptic drug used in children.
  • Optimal therapeutic levels for valproate are typically 50-100 mcg/ml.
  • Difficult-to-control generalized or mixed seizure disorders in pediatric patients pose treatment challenges.

Observation:

  • This study reviewed 25 pediatric patients with serum valproate levels exceeding the standard therapeutic range (100-200 mcg/ml).
  • Patients received valproate doses ranging from 50-100 mg/kg/day.
  • All patients presented with challenging-to-manage generalized or mixed seizure types.

Findings:

  • A significant decrease in seizure frequency (>50%) was observed in 14 patients.
  • Improved seizure control correlated with higher valproate serum levels, ranging from 111-196 mcg/ml.
  • No nondose-related side effects were documented during careful patient monitoring.

Implications:

  • Increasing valproate dosage to the maximum tolerated level may enhance clinical response in pediatric epilepsy.
  • Higher serum valproate concentrations appear safe and effective for specific pediatric seizure populations.
  • This suggests a potential strategy for optimizing valproate therapy in refractory epilepsy cases.

Related Experiment Videos